Home › Free Stock Grades › LXRX
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Grade
LXRX · Healthcare
A+
Market Cap
$417.5M
P/E Ratio
—
Revenue Growth (YoY)
+60.2%
Net Margin
-101.1%
Return on Equity
—
Dividend Yield
None
About Lexicon Pharmaceuticals, Inc.'s fundamentals
Lexicon Pharmaceuticals is a biotech company with a market capitalization of $417.5 million that demonstrated strong revenue growth of 60.2% year-over-year, indicating expanding commercial activity. However, the company is currently unprofitable, operating at a net margin of -101.1% and reporting a net loss in its latest annual statement, which is typical for development-stage biotechnology firms investing heavily in research and development. The company does not pay a dividend, with all resources directed toward operations and pipeline development.